Long intergenic non-protein coding RNA 1014 (LINC01014)

Long intergenic non-protein coding RNA 1014 (LINC01014) is a long intergenic non-coding RNA (lincRNA), meaning it is a long RNA transcript (>200 nucleotides) that does not encode protein and is transcribed from regions of the genome that do not overlap with protein-coding genes[1][3][5][7]. LINC01014 has been identified under multiple aliases including KCNMB2-IT1 and hCG1646471[1][3]. LINC01014 has been shown to be upregulated in esophageal cancer and is associated with promoting resistance to the kinase inhibitor gefitinib, suggesting a regulatory role in cancer drug response[2]. Like other lincRNAs, it may function in regulation of gene expression, epigenetic modification, and chromatin architecture, and is part of a rapidly evolving field with emerging roles in disease modulation, though it is not currently classified as a conventional therapeutic target (such as a receptor, enzyme, or transporter)[5][7].

Other names

KCNMB2-IT1KCNMB2 intronic transcript 1 (non-protein coding)hCG1646471LINC01014

No direct "mechanism of action" for drug-target interaction; reported involvement in promoting resistance to gefitinib, possibly through modulation of non-coding RNA-mediated regulatory pathways[2]